ASX:VIT

ASX ANNOUNCEMENT

7 SEPTEMBER 2026

Doctors on Demand Update

BUPA to redirect international-member telehealth referrals from Doctors on Demand

Melbourne, Australia – Vitura Health Limited (ASX: VIT) (**Vitura** and **Company**), a leading digital health business, today provides an update on the projected performance of its Doctors on Demand telehealth business in FY2027.

Acquired in October 2023 (FY2024), Doctors on Demand is Vitura's 24/7 virtual GP primary care telehealth service. It allows patients to consult face-to-face via video with a doctor about general health concerns or queries, diagnoses, or monitoring from preventative care through to chronic conditions.

Since 1 October 2022, Doctors on Demand has been a longstanding contracted partner of BUPA Australia Health Insurance, supporting its telehealth offering, Blua. Doctors on Demand's contract with BUPA has been renewed annually by the parties in accordance with a regular process and without incident.

Despite previous indications from BUPA, BUPA informed Vitura that it had initiated a small pilot program where overseas students currently using Doctors on Demand were automatically directed to another platform. BUPA has advised that from 9 September 2026, it will automatically redirect all international members currently serviced by Doctors on Demand (all overseas visitors and students) to Hola Health, an alternative platform in which BUPA holds a beneficial financial interest.

This is despite prior confirmation in May 2026 from BUPA to Doctors on Demand of its expected increased volume requirements for calendar years 2026 and 2027, on which Doctors on Demand based its resourcing and operating plans.

With international member referrals accounting for around 77% of Doctors on Demand's total BUPA patients, Doctors on Demand is now expected to realise a reduction of approximately $6 million in revenue in FY2027. The remaining 23%, being the domestic members, are expected to continue being referred to Doctors on Demand until the end of the current contract on 31 December 2026.

Despite this, Vitura reconfirms its view that the Group's FY2027 financial results are expected to be significantly improved on FY2026.

Vitura has issued a breach notification to BUPA and will continue to keep the market updated as required.

ENDS

Authorised by - The Board of Vitura Health Limited

Contact

Media & Investor Relations Enquiries
Dieter Lehmann
Nominis Communications
+61 427 672 995
dieter@nominis.me

Forward-looking statements

This announcement includes forward-looking statements which may be identified by words such as 'anticipates', 'believes', 'expects', 'intends', 'may', 'will', 'could', or 'should' and other similar words that involve risks and uncertainties. These forward-looking statements are based on the Company's expectations and beliefs concerning future events as at the date of this announcement. Forward-looking statements are necessarily subject to risks, uncertainties, and other factors, many of which are outside the control of the Company, which could cause actual results to differ materially from such statements. The Company makes no undertaking to update or revise the forward-looking statements made in this announcement to reflect any change in circumstances or events after the date of this announcement.

About Vitura Health Limited (ASX: VIT)

- www.vitura.com.au

Vitura Health Limited is diversified digital health business listed on the ASX (ASX: VIT) and, via its subsidiaries, operates the following businesses:

- www.burleighheadscannabis.com

Burleigh Heads Cannabis operates the market leading prescriber, patient, pharmacy, and supplier online ecosystem, Canview, which sells and distributes roughly 600 therapeutic product and device SKUs within Australia from roughly 70 international and domestic brands.

- www.canview.com.au

Canview was developed to be a complete end-to-end healthcare ecosystem designed to provide doctors, pharmacists, and patients with a simple and cost-effective way to facilitate the treatment of patients with increased efficiency and compliance. The Canview system is based on a medicines wholesaling platform which seamlessly brings together several disparate SAAS (software-as-a-service) providers including inventory control, invoicing, customer management, reporting and analytics, all linked together through customised integration software owned and operated by Vitura. Underpinning the suite of SAAS elements are several bespoke, internally generated operating procedures and intellectual property assets, supported by the Canview customer support and infield customer engagement teams. Through the in-house integration of the different elements which together make up Canview, the platform provides the best user experience in the industry.

Canview provides Australian doctors with the ability to integrate their patient management systems directly with the platform and to use their patient information to generate electronic prescriptions within the Canview platform, without the need to input the patient's details. Prescriptions are then sent directly to the Canview patient app where patients can manage their treatment and submit the prescription and subsequent repeats to one of the roughly 4,700 Australian pharmacies with accounts on Canview for dispensing.

- www.doctorsondemand.com.au

The Company owns Doctors on Demand Pty Ltd, a nationwide 24/7 x 365 telehealth platform business that provide innovative primary health solutions to hundreds of thousands of B2C and B2B patients annually.

Services include general medical consults, urgent care, medical certificates, pathology referrals, specialist referrals, men's health, women's health and medicated weight loss.

• www.cortexa.com.au

The Company owns 50% of Cortexa Pty Ltd, an incorporated joint venture with Canadian-based PharmAla Biotech (CSE: MDMA). Cortexa aims to be the leading supplier of psychedelics, GMP MDMA and GMP psilocybin, for research and therapeutic use in Australia.

• www.candor.com.au

The Company owns Candor Medical that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis and other speciality products and services.

• www.releaf.com.au

The Company owns a 42.5% equity interest in Flora Holdings Pty Ltd, a joint venture that owns and operates a series of medicinal cannabis clinics operating under the Releaf brand.

• www.cannadoc.com.au

The Company owns 75.5% of Cannadoc Health Pty Ltd, a medicinal cannabis clinic business that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.